ERBB2 and neoplasm: In particular, our results support the utility of therapy targeting extracellular matrix components for HER2-enriched breast cancer, in accordance with previous research reporting that dense extracellular matrix components around the tumor could block trastuzumab (Herceptin) targeting of HER236.